Corteva (NYSE:CTVA) Given New $10.00 Price Target at UBS Group

Key Points

• UBS cut its Corteva price target from $15 to $10 and maintained a “neutral” rating; the new target implied 9.11% upside from the reported share price.
• Corteva shares traded at $9.16, near their 52-week low of $9.01, according to the article.
• Recent headwinds include weak Brazilian demand and pricing, which prompted Corteva to lower its 2026 adjusted EPS outlook; a law firm has also announced an investigation into possible securities-law violations, which is not a finding of wrongdoing.

Corteva (NYSE:CTVA - Get Free Report) had its price target reduced by investment analysts at UBS Group from $15.00 to $10.00 in a report released on Friday, Benzinga reports. The firm currently has a "neutral" rating on the stock. UBS Group's price objective would suggest a potential upside of 9.11% from the company's current price.

Other research analysts have also recently issued reports about the company. BMO Capital Markets set a $15.00 price objective on Corteva in a research note on Friday, October 2nd. Deutsche Bank reiterated a "buy" rating and issued a $101.00 target price on shares of Corteva in a research report on Monday, August 3rd. Citigroup increased their price target on shares of Corteva from $86.00 to $91.00 and gave the stock a "neutral" rating in a report on Thursday, September 17th. KeyCorp upgraded shares of Corteva from a "sector weight" rating to an "overweight" rating and set a $17.00 price target on the stock in a report on Wednesday, October 7th. Finally, The Goldman Sachs Group reissued a "buy" rating and set a $20.00 price target on shares of Corteva in a research report on Thursday, October 8th. Fifteen investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $56.41.

Corteva Stock Performance

CTVA traded down $0.03 on Friday, reaching $9.16. 7,972,102 shares of the stock were exchanged, compared to its average volume of 8,291,812. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.52 and a quick ratio of 1.10. The company's 50-day moving average price is $38.81 and its 200 day moving average price is $69.88. The firm has a market capitalization of $6.11 billion, a PE ratio of 6.06, a PEG ratio of 1.69 and a beta of 0.58. Corteva has a fifty-two week low of $9.01 and a fifty-two week high of $90.97.

Institutional Trading of Corteva

Several hedge funds and other institutional investors have recently bought and sold shares of CTVA. Xcelsior Advisor Partners LLC boosted its position in Corteva by 26.6% in the 3rd quarter. Xcelsior Advisor Partners LLC now owns 24,281 shares of the company's stock worth $1,885,000 after purchasing an additional 5,107 shares in the last quarter. Bleakley Financial Group LLC increased its holdings in shares of Corteva by 12.5% during the 3rd quarter. Bleakley Financial Group LLC now owns 18,309 shares of the company's stock valued at $1,422,000 after purchasing an additional 2,032 shares in the last quarter. N.F.U. MUTUAL UNIT MANAGERS Ltd acquired a new position in shares of Corteva in the 3rd quarter valued at $1,325,000. Gabelli Funds LLC lifted its stake in shares of Corteva by 32.9% in the 3rd quarter. Gabelli Funds LLC now owns 46,500 shares of the company's stock valued at $3,611,000 after purchasing an additional 11,500 shares during the period. Finally, Advisors Asset Management Inc. acquired a new position in shares of Corteva in the 3rd quarter valued at $2,856,000. 81.54% of the stock is owned by institutional investors and hedge funds.

Recent Corteva Headlines

Investors following CTVA have been watching these headlines:

• Positive Sentiment: Corteva said strong sales growth from new products and operational improvements helped offset difficult market conditions, and management cited these efforts as part of its recovery plan. Corteva Q3 Earnings Call Highlights Brazil Woes and Outlook Cut
• Negative Sentiment: Brazil’s inventory glut, weaker demand, competitive pricing and lower volumes are weighing on sales and earnings. Corteva cut its 2026 adjusted EPS guidance to $0.76–$0.80, below the cited analyst consensus of $1.07; its shares fell sharply following the results and outlook update. Corteva shares slide after Brazil weakness prompts annual profit forecast cut
• Negative Sentiment: A law firm announced an investigation into whether Corteva violated securities laws. The announcement adds a legal overhang, though it is an investigation—not a finding of wrongdoing. Securities fraud investigation announcement

Corteva Company Profile

Corteva, Inc. is an agricultural science company that develops and supplies products and services for farmers. Its business focuses on seeds and crop protection, including technologies intended to help improve crop performance and manage weeds, insects, and plant diseases. Its seed portfolio includes corn, soybean, and other crop varieties, sold under brands such as Pioneer and Brevant. Corteva's crop protection offerings include herbicides, insecticides, fungicides, and biological products, alongside digital tools and services that support farm decision-making.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.